Biggest News Aggregation in the World
📰 David Angulo News

David Angulo News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from David Angulo. Real-time updates on events, politics, business and more.

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

JERSEY CITY, N.J., Jan. 05, 2024 -- SCYNEXIS, Inc. , a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today...
Irina Koffler David Angulo Ashraf Ibrahim National Institutes Of Health Exchange Commission National Institute Of Allergy

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy - SCYNEXIS (NASDAQ:SCYX)

JERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today
David Angulo Irina Koffler National Institute Of Allergy National Institutes Of Health Scynexis Inc Drug Administration

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Trial Begins for Vanesa Gastellu, 31, Accused of Gunning Down Friend in Chula Vista

A woman executed her former friend in Chula Vista because she believed the victim had caused her boyfriend to be fatally shot by police, a prosecutor said Wednesday, while a defense attorney argued the victim was actually shot to death by gang members who set her client up to take the fall.
Vanesa Gastellu Los Angeles Facebook Vanesa Gastellu Christine Garcia David Angulo Christina Garcia Christopher Rhoads

SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update - SCYNEXIS (NASDAQ:SCYX)

SCYNEXIS reported the closing of an exclusive license agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets). SCYNEXIS received an upfront payment of $90 million upon deal close.SCYNEXIS announced the
David Angulo Irina Koffler Hansoh Pharma Triterpenoid Antifungals Preclinical Development Program Hansoh Pharmaceutical Group Company

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science